
Corrie Detweiler, a professor of molecular, cellular and developmental biology, eyes some samples in the lab. (Photo: CU Boulder)
As scientists around the globe wage war against a novel, deadly virus, one CU Boulder lab is working on new weapons to battle a different microbial threat: a rising tide of antibiotic-resistant bacteria which, if left unchecked, could kill an estimated 10 million people annually by 2050.
“The COVID-19 situation is definitely putting us at risk for increasing resistance to antibiotics, so it’s more important now than ever that we come up with alternative treatments,” said Corrie Detweiler, a professor of molecular, cellular and developmental biology who has spent her career seeking those alternatives.
In a paper published Dec. 18 in the journal PLOS Pathogens, Detweiler and her research team unveil their latest discovery—a chemical compound that works with a host’s innate immune response to push past cellular barriers that help bacteria resist antibiotics.
Along with their other recently published discoveries, the authors say, the finding could lead to a new arsenal for fighting what could be the next big public health threat.
“If we don’t solve the problem of finding new antibiotics or somehow making old antibiotics work again, we are going to see sharply increasing deaths from bacterial infections we thought we had beaten decades ago,” said Detweiler. “This study offers a totally new approach and could point the way toward new drugs that work better and have fewer side effects.”
In the United States alone, 35,000 people die annually from bacterial infections that could not be treated because they’ve grown resistant to existing drugs. Countless others suffer life-threatening bouts with once-easily treatable illnesses like strep throat, urinary tract infections and pneumonia. By 2050, the authors note, there could be more deaths from antibiotic resistance than from cancer.
“As our existing antibiotics adapt and work less, we risk essentially going back to a period 100 years ago, when even a minor infection could mean death,” said Detweiler.
The pandemic has shone even more light on the problem, she notes, as many patients die not from the virus itself but from hard-to-treat secondary bacterial infections.
Meanwhile, she and other scholars worry that heightened use of antibiotics to prevent or treat those secondary infections, while at times necessary, may be exacerbating resistance.
“Fragile healthcare systems in many parts of the world may not withstand the COVID-19 pandemic if also faced with a substantial increase in antimicrobial resistance,” wrote the authors of an editorial in the British Medical Journal in November.
A new arsenal for an evolving war
Most antibiotics in use today were developed in the 1950s, and pharmaceutical companies have since scaled back on research in the field in favor of more profitable ventures.
To feed the pipeline, Detweiler’s lab developed a technique called SAFIRE for screening for new small molecules, which work differently than older drugs.
Of 14,400 candidates screened from a library of existing chemicals, SAFIRE identified 70 that hold promise.
The new paper centers around “JD1,” which appears to be particularly effective at infiltrating what are known as “Gram-negative bacteria.”
With a tough exterior membrane that prevents antibiotics from accessing the cell, and another interior membrane providing a buffer, these bacteria (including Salmonella and E. coli) are inherently difficult to treat.
But unlike other drugs, JD1 takes advantage of the host’s initial immune assault on that outer bacterial membrane, then slips inside and goes after the inner membrane too.
“This is the first study to show that you can target a Gram-negative bacteria’s inner membrane by exploiting the innate immune response of the host,” Detweiler said.
In laboratory and rodent experiments, JD1 reduced the survival and spread of Gram-negative bacteria called Salmonella enterica by 95%.
But while it damaged the bacterial cell membranes, it couldn’t penetrate the fine layer of cholesterol that lined its mammalian host’s cell membranes.
“Bacteria are vulnerable to JD1 in a way that our cells are not,” said Detweiler, noting that for this reason, side-effects would likely be minimal.
Further studies are underway to explore JD1 and other compounds like it.
Meanwhile, Detweiler has formed a spin-off company to help commercialize other compounds that work by inhibiting pumps, called “efflux pumps,” that bacteria use to pump out antibiotics.
“The reality is, evolution is way smarter than all of the scientists put together and these bacteria will continue to evolve to resist what we throw at them,” she said. “We cannot rest on our laurels. We have to keep feeding the pipeline.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Threat of superbugs
- Science’s cutting-edge: seven ideas you should know about in 2021on January 21, 2021 at 4:11 pm
From life-saving viruses to spaceship swarms to virtual reality therapy, here's our pick of the scientific research to look out for in the year ahead.
- Health officials worried pandemic may be contributing to spike in antibiotic-resistant 'superbugs'on January 21, 2021 at 3:51 pm
A new study published in the Clinical Infectious Diseases journal analyzed thousands of hospitalized kids across the country who had been prescribed antibiotics in 2016 and 2017. It found 26% either ...
- CBD could be used to treat anti-biotic resistant superbugson January 21, 2021 at 1:31 pm
It's been touted as a natural treatment for depression, anxiety, migraines, and even conditions like epilepsy. But new research shows that CBD could do even more as a potential new class of antibiotic ...
- Research breakthrough finds cannabis could treat gonorrhoea, meningitison January 20, 2021 at 6:30 pm
Antibiotic resistant infections like gonorrhoea could soon be treated by cannabis, as breakthrough research suggests the drug could be a potentially powerful tool in combating superbugs.
- Fighting antibiotic resistant superbugs with viruseson January 19, 2021 at 2:41 pm
There's been advances in the fight to combat antibiotic resistant superbugs. One of the Australian scientists at the forefront of this research Jeremy Barr of Monash University talks to Jesse about ...
Go deeper with Google Headlines on:
Threat of superbugs
Go deeper with Bing News on:
Antibiotic-resistant bacteria
- 9 out of 10 U.S. infants experience gut microbiome deficiencyon January 22, 2021 at 4:59 am
A new peer-reviewed study reveals that the vast majority of U.S. infants may be suffering from a substantial deficiency in an important bacterium key to breast milk digestion and immune system ...
- Health officials worried pandemic may be contributing to spike in antibiotic-resistant 'superbugs'on January 21, 2021 at 3:51 pm
A new study published in the Clinical Infectious Diseases journal analyzed thousands of hospitalized kids across the country who had been prescribed antibiotics in 2016 and 2017. It found 26% either ...
- As More Bacteria Grow Resistant to Antibiotics, Scientists Are Fighting Backon January 21, 2021 at 2:43 pm
USC experts search for answers to deadly superbugs and ways to keep them from spreading to you and the ones you love.
- CBD Destroys Antibiotic-Resistant Bacteria Such as Gonorrhea, Study Findson January 21, 2021 at 12:30 am
For the first time ever, researchers at the University of Queensland have found how cannabis can provide a solution to antibiotic-resistant bacteria. A non-psychoactive cannabinoid known as ...
- The Next Pandemic Is Already Hereon January 20, 2021 at 11:03 am
The casualties of a global pandemic are now vivid to everyone, and many wished we could have acted earlier to stem the death toll. But another pandemic has already started. It's not one that rips ...